UK Markets open in 5 hrs 44 mins
  • NIKKEI 225

    29,639.40
    -200.31 (-0.67%)
     
  • HANG SENG

    24,221.54
    +122.40 (+0.51%)
     
  • CRUDE OIL

    70.51
    -0.05 (-0.07%)
     
  • GOLD FUTURES

    1,768.40
    -9.80 (-0.55%)
     
  • DOW

    34,258.32
    +338.48 (+1.00%)
     
  • BTC-GBP

    32,596.48
    +999.15 (+3.16%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • Nasdaq

    14,896.85
    +150.45 (+1.02%)
     
  • ^FTAS

    4,081.81
    +52.80 (+1.31%)
     

Global Biopsy Guidance System Market Report 2021 - Increasing Prevalence of Cancer is a Major Factor for Market Growth

·5-min read

Dublin, Aug. 18, 2021 (GLOBE NEWSWIRE) -- The "Biopsy Guidance System Market Size, Share & Trends Analysis Report by Product (Stereotactic Guided Biopsy, MRI Guided Biopsy), by Application, by End-use (Hospitals, Specialty Clinics), by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

The global biopsy guidance system market size is expected to reach USD 1,383.5 million by 2028, expanding at a CAGR of 5.2%

The increasing prevalence of cancer, rise in the geriatric population, growing demand for non-invasive procedures, technological innovations, a rising number of government initiatives, and impact of COVID-19 are the key driving factors for the market.

A biopsy is one of the most prominent procedures for diagnosing cancer amongst other chronic diseases, and it is commonly employed in the diagnosis of breast, brain, skin, and prostate cancer. The increasing prevalence of cancer is a major factor responsible for market growth.

For instance, according to Cancer.org, in 2021, around 1.9 million new cancer cases are expected to be diagnosed in the US. Since, the biopsy guidance system is one of the major requirements for the initial diagnosis of cancer, thus, rising number of cancer cases is anticipated to propel market growth over the forecast period

Furthermore, there is a rising preference for minimally invasive biopsy treatments in the market. During the forecast period, several types of technologies and products including robot-assisted biopsy guidance systems, needle-based biopsy guns, and vacuum-assisted core biopsy systems, are expected to expand rapidly.

For instance, in March 2021, IZI Medical Products, LLC launched Quick-Core Auto Biopsy System for soft tissue biopsy. It is a lightweight, completely automatic biopsy device and provides reliability, quality, and accuracy. Additionally, rising awareness of breast cancer treatment and diagnosis will further boost market growth over the forecast period.

Biopsy Guidance System Market Report Highlights

  • In terms of product, the stereotactic guided biopsy segment held the largest revenue share in 2020 and the ultrasound-guided biopsy segment is estimated to be the fastest-growing segment over the forecast period

  • In terms of application, the brain biopsy segment held the largest revenue share in 2020 and the breast biopsy segment is estimated to be the fastest-growing segment during the forecast period. The rising prevalence of brain cancer is the major factor driving the demand for brain biopsies

  • In terms of end-use, the hospital segment held the largest revenue share in 2020. The hospital segment's dominance is majorly attributed to the higher biopsy guiding system utilization in hospitals

  • North America dominated the market in 2020 owing to numerous factors such as enhanced infrastructure, rising patient awareness, and the presence of key players in the region

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Objectives

Chapter 3 Executive Summary
3.1 Market Outlook
3.2 Segment Outlook
3.3 Competitive Insights
3.3.1 Market Segmentation
3.4 Market Snapshot

Chapter 4 Biopsy Guidance Systems Market Variables, Trends & Scope
4.1 Market Lineage Outlook
4.1.1 Parent market outlook
4.1.2 Ancillary Market
4.2 Penetration & Growth Prospect Mapping
4.3 Regulatory Framework
4.4 Market Dynamics
4.4.1 Market driver analysis
4.4.1.1 Rising prevalence of cancer
4.4.1.2 Increasing preference for non-invasive procedures
4.4.1.3 Technological advancements
4.4.2 Market restraint analysis
4.4.2.1 Stringent manufacturing policies
4.4.2.2 High cost of biopsy guidance systems
4.5 Biopsy Guidance Systems Market Analysis Tools
4.5.1 SWOT Analysis, by PEST
4.5.2 Porter's five forces analysis

Chapter 5 Biopsy Guidance Systems Market: Segment Analysis, By Product, 2016 - 2028 (USD Million)
5.1 Definitions & Scope
5.2 Product Market Share Analysis, 2020 & 2028
5.3 Biopsy Guidance Systems Market, by Product, 2016 to 2028
5.4 Market Size Forecasts and Trend Analysis
5.4.1 Stereotactic guided biopsy
5.4.2 Ultrasound guided biopsy
5.4.3 MRI guided biopsy

Chapter 6 Biopsy Guidance Systems Market: Segment Analysis, By Application, 2016 - 2028 (USD Million)
6.1 Definitions & Scope
6.2 Application Market Share Analysis, 2020 & 2028
6.3 Biopsy Guidance Systems Market, by Application, 2016 to 2028
6.4 Market Size Forecasts and Trend Analysis
6.4.1 Brain biopsy
6.4.2 Breast biopsy

Chapter 7 Biopsy Guidance Systems Market: Segment Analysis, By End Use, 2016 - 2028 (USD Million)
7.1 Definitions & Scope
7.2 End-use Market Share Analysis, 2020 & 2028
7.3 Biopsy Guidance Systems Market, By End Use, 2016 to 2028
7.4 Market Size Forecasts and Trend Analysis
7.4.1 Hospitals
7.4.2 Specialty clinics
7.4.3 Diagnostic centers
7.4.4 Research and academic institutes

Chapter 8 Biopsy Guidance Systems Market: Regional Market Analysis, By Product, Application, and End-use, 2016 - 2028 (USD Million)
8.1 Definitions & Scope
8.2 Regional Market Share Analysis, 2020 & 2028
8.3 Regional Market Snapshot
8.4 Market Size Forecasts & Trend Analysis

Chapter 9 Biopsy Guidance Systems Market: Competitive Analysis
9.1 Company overview
9.2 Financial performance
9.3 Product benchmarking
9.4 Strategic initiatives

  • Becton, Dickinson and Company

  • Hologic, Inc.

  • Devicor Medical Products, Inc.

  • B. Braun Melsungen AG

  • ARGON MEDICAL

  • Boston Scientific Corporation

  • INRAD Inc.

  • Cook Medical

  • PLANMED OY

For more information about this report visit https://www.researchandmarkets.com/r/1a00g0

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting